Sichuan Duorui - Retatrutide
COA 6724 Inquiries
2381089-83-2
Pharmaceutical Grade
99%
Chengdu
depends on customers' needs
2025-12-27
Semaglutide,Tirzepatide,Retatrutide,Lanreotide Acetate,Pegcetacoplan
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRetatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.CertificatesBasic Info
-
Product Name:
Retatrutide
Other Name:Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide
CAS No.:2381089-83-2
Molecular Formula:C221H342N46O68
Molecular Weight:4731.33
EC Number:200-001-8
Color/Form:White lyophilized
Categories:
Characteristics-
Water Solubility:
Soluble in water (5mg/ml).
Storage Conditions:-20°C
Critical Temperature & Pressure:-20°C
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Tirzepatide,Retatrutide,Lanreotide Acetate,Pegcetacoplan
-
Location:
No. 76 Jinle Road, Chengdu-Aba Industrial Concentration Development Zone, Jintang County, Chengdu City, Sichuan Province, China
-
Payment Terms:
TT against copy of documents,L/C,100% TT in advance
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
101-200
-
Year of Establishment:
2018
-
-
Inquiry History6724 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Retatrutide 2381089-83-2
3 MT Mar 28, 2026 
United Kingdom
Retatrutide - 2381089-83-2
1 G Feb 10, 2026
United States
Retatrutide CAS 2381089-83-2 10mg vial
20 MT Mar 7, 2026
United States
Factory Retatrutide API 99% Purity CAS 2381089-83-2
5 KG Nov 10, 2025
United Kingdom
Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA
1 MT Mar 22, 2026
United States
2381089-83-2
100 G Jul 14, 2026
United States
2381089-83-2
100 G Feb 24, 2026
United States
2381089-83-2
100 MT Dec 9, 2023
United States
Retatrutide 2381089-83-2
200 MG May 16, 2026
United Kingdom
2381089-83-2 retatrutide
300 MG Feb 13, 2026
United States
Retatrutide 2381089-83-2 wholesale
500 MT Nov 3, 2023 
Austria
Retatrutide CAS 2381089-83-2 10mg vial
20 PCS Feb 10, 2026 
Poland
CAS 2381089-83-2 (Custom Peptide)
40 MT Apr 10, 2026
Austria
Peptide Retatruide CAS 2381089-83-2
100 MT Apr 4, 2026
United States
GLP-1 / GIP Retatrutide cas 2381089-83-2
1 MT Oct 16, 2024
United States
Retatrutide CAS 2381089-83-2 99%
10 PCS Feb 21, 2026
United States
Tirzepatide 99.9% Liquid 2381089-83-2 TeruiOP
1 MT Sep 6, 2023
United States
Retatrutide/LY3437943/GIPR/GLP-1R 98% Powder 2381089-83-2 Senwayer
1 G Sep 3, 2023 
Palestine
Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service
10 MG Mar 16, 2026
United States
Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service
20 MG Feb 4, 2026 Post an enquiry for this product